Hematology

Filter

gene therapy

EAHAD 2026: Nine-Year Outcomes of Gene Therapy

February 2026

Nine-year data show sustained safety and reduced bleeding after gene therapy in haemophilia B, although enrichment for full viral capsids did not deliver clear clinical advantages.

Frederik-Schjesvold

Hema Now: Episode 10: Shaping the Future of Myeloma

Fredrik Schjesvold, Head of the Oslo Myeloma Center, Oslo University Hospital, and Head of the Norwegian myeloma association joins the show.

Increased Cancer Risk After Cerebral Venous Thrombosis

CVT patients face a significantly higher cancer risk, especially in the first year and up to 10 years after diagnosis.

Increased Risk of Skin Cancer After Blood or Marrow Transplant

BMT survivors face a higher risk of skin cancer, with age, graft-vs-host disease, and treatment influencing outcomes.

Immune Checkpoint Inhibitor Before Allogeneic Transplant Boosts Survival in Hodgkin Lymphoma

ICI treatment before transplant enhances survival in relapsed Hodgkin lymphoma, though it increases the risk of acute GVHD.

Detectable Antibodies Lower COVID-19 Risk in Immunosuppressed

Detectable antibodies reduce COVID-19 risk in immunosuppressed individuals, emphasizing the need for tailored protection strategies.

Gene-Editing Therapy for Sickle Cell Disease Approved by NHS

The NHS has approved exa-cel, a revolutionary gene-editing therapy for sickle cell disease, offering hope for a cure.

Shared Care Model for Hematopoietic Cell Transplantation Shows Promise

Shared care after HCT improves quality of life at day 100 without affecting survival, offering a viable post-transplant model.

Key Metabolic Vulnerability in Multiple Myeloma Treatment

New research identifies VLCFA metabolism as a target to boost multiple myeloma treatment efficacy and combat drug resistance.

Loading posts...

« Previous 1 … 25 26 27 28 29 … 100 Next »